Clinical trials on Ampulla of Vater Carcinoma

  • CT-EU-00112125

    Analysis of dostarlimab as a first-line drug in the treatment of advanced non-colorectal cancers

    This clinical trial is focused on evaluating the effectiveness of an immunotherapy called dostarlimab for patients with certain types of advanced cancers that are not suitable for surgery. These cancers include pancreatic adenocarcinoma, carcinoma of the ampulla of Vater, adrenocortical carcinoma, high-grade neuroendocrine carcinoma, soft tissue sarcoma, and cancers of the small bowel, duodenum, and stomach. The study is specifically for those cancers that have a condition known as deficient mismatch repair (dMMR) or microsatellite instability (MSI), which are factors that can affect how a cancer responds to treatment.

    In this study, patients will be divided into two groups. One group will receive dostarlimab as a first-line treatment, which means it’s the first treatment given for their cancer. Dostarlimab is given through an IV (intravenously) and works by helping the immune system fight cancer. The other group will receive standard chemotherapy treatments, which are drugs used to kill cancer cells directly.

    An important aspect of this trial is that if patients in the chemotherapy group do not respond well to treatment and their cancer progresses, they may have the option to switch to the dostarlimab treatment, following a waiting period after their last dose of chemotherapy.

    The main goal of the study is to see if patients treated with dostarlimab live longer without their cancer getting worse compared to those receiving chemotherapy. This is known as progression-free survival.

    Before joining the study, patients will go through a screening process to confirm their eligibility, including tests to confirm their cancer has the dMMR/MSI condition. The trial will also involve regular check-ups to monitor how the cancer responds to the treatment and to check for any side effects.

    This study is an opportunity for patients with these specific types of advanced cancers to receive a new type of immunotherapy that could potentially offer better outcomes than standard chemotherapy.

    • Dostarlimab